Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Filters applied: . Clear all
Page 1
Positive Vasoreactivity Testing in Pulmonary Arterial Hypertension: Therapeutic Consequences, Treatment Patterns, and Outcomes in the Modern Management Era.
Gerhardt F, Fiessler E, Olsson KM, Kayser MZ, Kovacs G, Gall H, Ghofrani HA, Badr Eslam R, Lang IM, Benjamin N, Grünig E, Halank M, Lange TJ, Ulrich S, Leuchte H, Held M, Klose H, Ewert R, Wilkens H, Pizarro C, Skowasch D, Wissmüller M, Hellmich M, Olschewski H, Hoeper MM, Rosenkranz S. Gerhardt F, et al. Among authors: lang im. Circulation. 2024 Apr 12. doi: 10.1161/CIRCULATIONAHA.122.063821. Online ahead of print. Circulation. 2024. PMID: 38606558
At 12 months, 53.2% remained on CCB monotherapy, 14.7% on initial CCB plus another initial PAH therapy, and the remaining patients had the CCB withdrawn or PAH therapy added. CCB long-term response was found in 54.3% of patients. Five-year survival was 98.5% in long-ter …
At 12 months, 53.2% remained on CCB monotherapy, 14.7% on initial CCB plus another initial PAH therapy, and the remaining patients had the C …
Developmental or Procedural Vena Cava Interruption and Venous Thromboembolism: A Review.
Bikdeli B, Sadeghipour P, Lou J, Bejjani A, Khairani CD, Rashedi S, Lookstein R, Lansky A, Vedantham S, Sobieszczyk P, Mena-Hurtado C, Aghayev A, Henke P, Mehdipoor G, Tufano A, Chatterjee S, Middeldorp S, Wasan S, Bashir R, Lang IM, Shishehbor MH, Gerhard-Herman M, Giri J, Menard MT, Parikh SA, Mazzolai L, Moores L, Monreal M, Jimenez D, Goldhaber SZ, Krumholz HM, Piazza G. Bikdeli B, et al. Among authors: lang im. Semin Thromb Hemost. 2024 Jan 4. doi: 10.1055/s-0043-1777991. Online ahead of print. Semin Thromb Hemost. 2024. PMID: 38176425
Surgical techniques for vena cava interruption (ligation, clipping, and plication) to prevent PE have been largely abandoned due to short-term procedural risks and long-term complications, although survivors of prior procedures are occasionally encountered. ...
Surgical techniques for vena cava interruption (ligation, clipping, and plication) to prevent PE have been largely abandoned due to short- …
The risk profile change in patients with severe chronic thromboembolic pulmonary hypertension treated with subcutaneous treprostinil.
Jansa P, Kopeć G, Torbicki A, Sadushi-Kolici R, Campean IA, Halank M, Simkova I, Steringer-Mascherbauer R, Salobir B, Klepetko W, Lindner J, Lang IM. Jansa P, et al. Among authors: lang im. Pulm Circ. 2023 Aug 21;13(3):e12274. doi: 10.1002/pul2.12274. eCollection 2023 Jul. Pulm Circ. 2023. PMID: 37609358 Free PMC article.
Chronic thromboembolic pulmonary hypertension (CTEPH) is successfully treatable with pulmonary endarterectomy (PEA), balloon pulmonary angioplasty, and medical therapy. Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management risk score ( …
Chronic thromboembolic pulmonary hypertension (CTEPH) is successfully treatable with pulmonary endarterectomy (PEA), balloon pulmonary angio …
Chronic thromboembolic pulmonary hypertension: realising the potential of multimodal management.
Delcroix M, de Perrot M, Jaïs X, Jenkins DP, Lang IM, Matsubara H, Meijboom LJ, Quarck R, Simonneau G, Wiedenroth CB, Kim NH. Delcroix M, et al. Among authors: lang im. Lancet Respir Med. 2023 Sep;11(9):836-850. doi: 10.1016/S2213-2600(23)00292-8. Epub 2023 Aug 14. Lancet Respir Med. 2023. PMID: 37591299 Review.
Further work is needed to optimise the use and combination of multimodal therapeutic options in CTEPH to improve long-term outcomes for patients....
Further work is needed to optimise the use and combination of multimodal therapeutic options in CTEPH to improve long-term outcomes f …
Left Ventricular Filling Pressure in Chronic Thromboembolic Pulmonary Hypertension.
Gerges C, Pistritto AM, Gerges M, Friewald R, Hartig V, Hofbauer TM, Reil B, Engel L, Dannenberg V, Kastl SP, Skoro-Sajer N, Moser B, Taghavi S, Klepetko W, Lang IM. Gerges C, et al. Among authors: lang im. J Am Coll Cardiol. 2023 Feb 21;81(7):653-664. doi: 10.1016/j.jacc.2022.11.049. J Am Coll Cardiol. 2023. PMID: 36792280 Free article.
Two cutoffs were applied to identify patients with elevated LVFP: 1) for the primary analysis mPAWP and/or LVEDP >15 mm Hg, as recommended by the current pulmonary hypertension guidelines; and 2) for the secondary analysis mPAWP and/or LVEDP >11 mm Hg, representing the uppe …
Two cutoffs were applied to identify patients with elevated LVFP: 1) for the primary analysis mPAWP and/or LVEDP >15 mm Hg, as recommende …
Early selexipag initiation and long-term outcomes: insights from randomised controlled trials in pulmonary arterial hypertension.
Coghlan JG, Gaine S, Channick R, Chin KM, du Roure C, Gibbs JSR, Hoeper MM, Lang IM, Mathai SC, McLaughlin VV, Mitchell L, Simonneau G, Sitbon O, Tapson VF, Galiè N. Coghlan JG, et al. Among authors: lang im. ERJ Open Res. 2023 Jan 16;9(1):00456-2022. doi: 10.1183/23120541.00456-2022. eCollection 2023 Jan. ERJ Open Res. 2023. PMID: 36687361 Free PMC article.
Further understanding of when to initiate therapies in pulmonary arterial hypertension (PAH) is important to improve long-term outcomes. Post hoc analyses of GRIPHON (NCT01106014) and exploratory analyses of TRITON (NCT02558231) suggested benefit of early selexipag initiat …
Further understanding of when to initiate therapies in pulmonary arterial hypertension (PAH) is important to improve long-term outcom …
Recovery of right ventricular function after intermediate-risk pulmonary embolism: results from the multicentre Pulmonary Embolism International Trial (PEITHO)-2.
Mavromanoli AC, Barco S, Ageno W, Bouvaist H, Brodmann M, Cuccia C, Couturaud F, Dellas C, Dimopoulos K, Duerschmied D, Empen K, Faggiano P, Ferrari E, Galiè N, Galvani M, Ghuysen A, Giannakoulas G, Huisman MV, Jiménez D, Kozak M, Lang IM, Meneveau N, Münzel T, Palazzini M, Petris AO, Piovaccari G, Salvi A, Schellong S, Schmidt KH, Verschuren F, Schmidtmann I, Toenges G, Klok FA, Konstantinides SV; PEITHO-2 Investigators. Mavromanoli AC, et al. Among authors: lang im. Clin Res Cardiol. 2023 Oct;112(10):1372-1381. doi: 10.1007/s00392-022-02138-4. Epub 2022 Dec 21. Clin Res Cardiol. 2023. PMID: 36539534 Free PMC article. Clinical Trial.
Almost one in four patients, however, continued to have evidence of RV dysfunction over the long term....
Almost one in four patients, however, continued to have evidence of RV dysfunction over the long term....
Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Benza RL, Langleben D, Hemnes AR, Vonk Noordegraaf A, Rosenkranz S, Thenappan T, Hassoun PM, Preston IR, Ghio S, Badagliacca R, Vizza CD, Lang IM, Meier C, Grünig E. Benza RL, et al. Among authors: lang im. Eur Respir Rev. 2022 Oct 5;31(166):220061. doi: 10.1183/16000617.0061-2022. Print 2022 Dec 31. Eur Respir Rev. 2022. PMID: 36198418 Free PMC article. Review.
Right ventricular dysfunction, hypertrophy and maladaptive remodelling are consequences of increased right ventricular (RV) afterload in PAH and CTEPH and are indicative of long-term outcomes. Because RV failure is the main cause of morbidity and mortality in PAH and CTEPH …
Right ventricular dysfunction, hypertrophy and maladaptive remodelling are consequences of increased right ventricular (RV) afterload in PAH …
Aggressive Afterload Lowering to Improve the Right Ventricle: A New Target for Medical Therapy in Pulmonary Arterial Hypertension?
Vizza CD, Lang IM, Badagliacca R, Benza RL, Rosenkranz S, White RJ, Adir Y, Andreassen AK, Balasubramanian V, Bartolome S, Blanco I, Bourge RC, Carlsen J, Camacho REC, D'Alto M, Farber HW, Frantz RP, Ford HJ, Ghio S, Gomberg-Maitland M, Humbert M, Naeije R, Orfanos SE, Oudiz RJ, Perrone SV, Shlobin OA, Simon MA, Sitbon O, Torres F, Luc Vachiery J, Wang KY, Yacoub MH, Liu Y, Golden G, Matsubara H. Vizza CD, et al. Among authors: lang im. Am J Respir Crit Care Med. 2022 Apr 1;205(7):751-760. doi: 10.1164/rccm.202109-2079PP. Am J Respir Crit Care Med. 2022. PMID: 34905704 Free PMC article.
Some data suggest that reaching threshold levels for pressure or resistance (components of right ventricular afterload) may be key to interrupting the self-perpetuating injury of pulmonary vascular disease in pulmonary arterial hypertension and could translate into improved long- …
Some data suggest that reaching threshold levels for pressure or resistance (components of right ventricular afterload) may be key to interr …
Plasma Trimethylamine-N-Oxide Is an Independent Predictor of Long-Term Cardiovascular Mortality in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome.
Eyileten C, Jarosz-Popek J, Jakubik D, Gasecka A, Wolska M, Ufnal M, Postula M, Toma A, Lang IM, Siller-Matula JM. Eyileten C, et al. Among authors: lang im. Front Cardiovasc Med. 2021 Oct 29;8:728724. doi: 10.3389/fcvm.2021.728724. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 34778397 Free PMC article.
High TMAO level is a strong and independent predictor of long-term CV mortality among patients presenting with ACS....
High TMAO level is a strong and independent predictor of long-term CV mortality among patients presenting with ACS....
73 results